磷酸化Girdin蛋白在乳腺癌中的表达及意义

Expression and significance of phosphorylated Girdin in breast cancer

目的探讨乳腺癌组织中磷酸化Girdin蛋白的表达与乳腺癌临床病理特征和分子分型的关系。方法应用免疫组化SP法检测27例乳腺小叶增生、61例乳腺导管原位癌和94例乳腺非特殊型浸润性导管癌组织中磷酸化Girdin蛋白的表达情况。结果磷酸化Girdin蛋白定位于细胞浆和（或）细胞核。磷酸化Girdin蛋白在乳腺小叶增生、乳腺导管原位癌和乳腺非特殊型浸润性导管癌中的阳性表达率分别为25．9％（7／27）、39．3％（24／61）和66．0％（62／94），差异有统计学意义（x^2=26．724，P〈0．001）。磷酸化Girdin蛋白的表达与乳腺非特殊型浸润性导管癌的病理学分期（r=0．204，P=0．049）、淋巴结转移（r=0．212，P=0．041）以及人表皮生长因子受体2（HER-2）的状态（r=0．248，P：0．016）呈正相关，而与组织学分级（r=-0．015，P=0．918）、患者年龄（r=-0．011，P=0．918）、肿瘤大小（r=0．075，P=0．471）、ER状态（r=0．071，P=0．498）、PR状态（r=-0．050，P=0．634）无关。磷酸化Girdin蛋白在管腔A型、管腔B型、HER-2（＋）型和三阴性乳腺非特殊型浸润性导管癌中的阳性表达率分别为55．8％、95．8％、66．7％和41．7％，差异有统计学意义（x^2=14．017，P=0．003）。结论磷酸化Girdin蛋白的表达与乳腺癌的恶性进展密切相关，其有可能成为乳腺癌临床治疗的新靶点。

Objective To detect the expression of phosphorylated girdin （p-girdin） in breast cancer and its association with pathological characteristics and molecular subtypes of breast cancer. Metimds Irmmmohistoehemical SP staining was used to investigate the expression of p-girdin in 27 cases of lobular hyperplasia of mammary gland, 61 cases of ductal carcinoma in situ （DCIS）, and 94 cases of non-special type invasive carcinoma （IDC-NOS） of breast. Results p-girdin was located in the cell cytoplasm and （or） nuclei in breast cancer. There was statistically a very significant difference among lobular hyperplasia, DCIS and IDC-NOS （X^2 =26. 724, P 〈0. 001 ）. Its cytoplasmic and nuclear reactivity were 25.9% （7/27）, 39.3% （24/61）, and 66.0% （62/94）, respectively. The expression of p-girdin was positively associated with pathologic stage （r =0. 204, P = 0. 049）, lymph node metastasis （r = 0. 212, P = 0. 041 ） and HER2/neu （r = 0. 248 ,P =0. 016）. But no significant association was identified between p-girdin expression and histological grade （r = -0.015, P =0.918）, age of patients （r = -0.011, P =0. 918）, tumor size （r =0.075 ,P = 0.471 ）, ER（ r = 0. 071, P = 0. 498 ）, PR （ r = - 0. 050, P = 0. 634 ）. Mann-Whitney test showed that p-girdin expression in luminal A, luminal B, triple negative and HER-2 （ ＋ ） type was significantly different （X^2 = 14. 017, P = 0. 003 ）. Among the four types, its positive rate was 55.8 % （24/43）, 95.8% （23/24）, 66.7% （ 10/15）, and 41.7% （5/12）, respectively. Conclusions p-Girdin expression is closely correlated with the malignant progression of breast cancer. Its expression may have clinical value as a new target for the treatment of breast cancer.